As UCB attends the 2018 American Epilepsy Society meeting in New Orleans, Louisiana this week, Mike Davis, Head of UCB’s U.S. Neurology Patient Value Unit, talks about the importance of using innovative approaches to shorten the time it takes a patient to get control of their condition. The following is an excerpt from his LinkedIn article, “Starting from a Patient Perspective Focuses Epilepsy Treatment Progress.” Read the full article on LinkedIn.

We’re excited to announce the 2019 UCB Family Epilepsy Scholarship Program™ is now open for applications. The program offers educational scholarships to people living with epilepsy, family members, and caregivers to help them fulfill their dreams. If you’re a high school senior, college, or graduate student in the epilepsy community looking for financial support to further your education, we invite you to keep reading.

This November, Epilepsy Awareness Month, we’re shining a spotlight on epilepsy – a patient community that’s near to our hearts and a research area we have been committed to for many years. Each day, we commit to helping people living with epilepsy like LaKeisha, patient advocate and life coach, achieve their dreams. 

UCB is pleased to announce 32 recipients were awarded the 2018 UCB Family Epilepsy Scholarship. This year’s winners are beginning their academic year at 31 schools across the country where awards will support their undergraduate or graduate education. Hailing from 17 states, this diverse group of passionate advocates includes people living with epilepsy or caregiving for someone living with epilepsy, including parents and siblings.

As one of the first winners of the UCB Family Epilepsy Scholarship, Maria reflects on the goals, choices, and experiences that have shaped her ever-evolving career in science.

Edward (Eddy) Han-Burgess was recently invited to attend the Aspen Ideas Festival Spotlight Health as a PhRMA Aspen Scholar. He joined four other emerging leaders from the biopharma industry from AstraZeneca, Eli Lilly and Company, Merck, and Novartis for a series of events on the new era of medicine and as a conference participant. 

• BRIVIACT^® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
• Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
• Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,^{1, 2}
• Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.

This spring, UCB engaged the Atlanta community at the 2018 Atlanta Science Festival with a booth called “How the Canine Mind Helps People with Severe Diseases.” The festival is a two-week celebration of science offering more than 100 events at locations throughout metro Atlanta. UCB participated at the expo event held in Piedmont Park on March 24. 

Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),¹ an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen